Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
Br J Cancer
; 99(1): 51-6, 2008 Jul 08.
Article
em En
| MEDLINE
| ID: mdl-18542071
ABSTRACT
The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. In this study, pooled data from two phase II trials of pemetrexed and carboplatin (PC) as first-line therapy were retrospectively analysed for comparisons between age groups. Patients received pemetrexed 500 mg m(-2) and carboplatin AUC 5 mg ml(-1) min(-1) intravenously every 21 days with standard vitamin supplementation. Elderly patients were defined as those >or=70 years old. A total of 178 patients with an ECOG performance status of
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pleurais
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Carboplatina
/
Glutamatos
/
Guanina
/
Mesotelioma
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article